Incyte Corp. (INCY) announced positive results after the close Monday from COMFORT-I, the Phase III clinical trial of INCB18424 in patients with myelofibrosis. The stock is now up 0.82 on 132K shares.
Incyte Corp. traded in a range for the bulk of Monday's session and closed up by 0.16 at $15.18. The stock finished near the lower end of over a one-month range.
For comments and feedback contact: editorial@rttnews.com